PET/CT scan changes during chemo with immune therapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed metastatic stage IV non-small cell lung cancer (NSCLC) based on biopsy/cell sample and imaging
- You have not yet received chemotherapy or immune therapy for your advanced stage cancer
- Your planned treatment must be a platinum “doublet” chemotherapy together with a PD-1 or PD-L1 inhibitor
- You are at least 18 years old and can sign consent and follow the study requirements
- Your general condition is good enough (ECOG performance status 0–2), and blood/organ labs are within required limits
- You do not have certain other conditions that could interfere with scans (like uncontrolled infection or specific immune-system diseases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
This trial tests whether a special PET scan can predict how well your tumor responds to an immunotherapy drug given before surgery. Participation may help doctors tailor your treatment and improve outcomes for early-stage lung cancer.
This study tests if a new type of PET scan can see changes in your immune system when you receive immunotherapy for non-small cell lung cancer. It may help doctors understand how well your treatment is working.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
Hear when a new Metastatic Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.